Imbioray (Hangzhou) Biomedicine Co., Ltd.
4 clinical trials · Sponsor
◉ Watch Imbioray (Hangzhou) Biomedicine Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma (NCT07087158) | Imbioray (Hangzhou) Biomedicine Co., Ltd. | 2025-09-08 |
| The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma (NCT07073833) | Imbioray (Hangzhou) Biomedicine Co., Ltd. | 2025-07-01 |
| Study of IBR733 Cell Injection in Acute Myeloid Leukemia (NCT06234904) | Imbioray (Hangzhou) Biomedicine Co., Ltd. | 2024-03-26 |
| Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors (NCT06001684) | Imbioray (Hangzhou) Biomedicine Co., Ltd. | 2023-09-01 |
Track Imbioray (Hangzhou) Biomedicine Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.